Global Blood Therapeutics, an early-stage biotech developing a small molecule therapy for sickle cell disease, announced terms for its IPO on Friday.
The South San Francisco, CA-based company plans to raise $102 million by offering 6.0 million shares at a price range of $16 to $18. At the midpoint of the proposed range, it would command a fully diluted market value of $528 million.
Global Blood Therapeutics, which was founded in 2011, plans to list on the Nasdaq under the symbol GBT. Morgan Stanley and Goldman Sachs are the joint bookrunners on the deal. It is expected to price during the week of August 10, 2015.
